Xeljanz (tofacitnib) Drug - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB509240756

Publication Date:

September 24, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Tofacitinib, sold under the brand听Xeljanz听among others, is a medication used to treat听rheumatoid arthritis,听psoriatic arthritis, and听ulcerative colitis
The global market for Xeljanz (tofacitnib) Drug was estimated to be worth US$ 1754 million in 2023 and is forecast to a readjusted size of US$ 1119.5 million by 2030 with a CAGR of -5.7% during the forecast period 2024-2030
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Xeljanz (tofacitnib) Drug, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Xeljanz (tofacitnib) Drug by region & country, by Type, and by Application.
The Xeljanz (tofacitnib) Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Xeljanz (tofacitnib) Drug.
Market Segmentation
By Company
Pfizer
Segment by Type:
Tablets
Extended-release Tablets
Segment by Application
Rheumatoid Arthritis
Psoriatic Arthritis
Other
By Region
North America
the United States
Canada
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Xeljanz (tofacitnib) Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Xeljanz (tofacitnib) Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Xeljanz (tofacitnib) Drug in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Market Overview
1.1 Xeljanz (tofacitnib) Drug Product Introduction
1.2 Global Xeljanz (tofacitnib) Drug Market Size Forecast
1.2.1 Global Xeljanz (tofacitnib) Drug Sales Value (2019-2030)
1.2.2 Global Xeljanz (tofacitnib) Drug Sales Volume (2019-2030)
1.2.3 Global Xeljanz (tofacitnib) Drug Sales Price (2019-2030)
1.3 Xeljanz (tofacitnib) Drug Market Trends & Drivers
1.3.1 Xeljanz (tofacitnib) Drug Industry Trends
1.3.2 Xeljanz (tofacitnib) Drug Market Drivers & Opportunity
1.3.3 Xeljanz (tofacitnib) Drug Market Challenges
1.3.4 Xeljanz (tofacitnib) Drug Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Xeljanz (tofacitnib) Drug Players Revenue Ranking (2023)
2.2 Global Xeljanz (tofacitnib) Drug Revenue by Company (2019-2024)
2.3 Global Xeljanz (tofacitnib) Drug Players Sales Volume Ranking (2023)
2.4 Global Xeljanz (tofacitnib) Drug Sales Volume by Company Players (2019-2024)
2.5 Global Xeljanz (tofacitnib) Drug Average Price by Company (2019-2024)
2.6 Key Manufacturers Xeljanz (tofacitnib) Drug Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Xeljanz (tofacitnib) Drug Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Xeljanz (tofacitnib) Drug
2.9 Xeljanz (tofacitnib) Drug Market Competitive Analysis
2.9.1 Xeljanz (tofacitnib) Drug Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Xeljanz (tofacitnib) Drug Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Xeljanz (tofacitnib) Drug as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Tablets
3.1.2 Extended-release Tablets
3.2 Global Xeljanz (tofacitnib) Drug Sales Value by Type
3.2.1 Global Xeljanz (tofacitnib) Drug Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Xeljanz (tofacitnib) Drug Sales Value, by Type (2019-2030)
3.2.3 Global Xeljanz (tofacitnib) Drug Sales Value, by Type (%) (2019-2030)
3.3 Global Xeljanz (tofacitnib) Drug Sales Volume by Type
3.3.1 Global Xeljanz (tofacitnib) Drug Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Xeljanz (tofacitnib) Drug Sales Volume, by Type (2019-2030)
3.3.3 Global Xeljanz (tofacitnib) Drug Sales Volume, by Type (%) (2019-2030)
3.4 Global Xeljanz (tofacitnib) Drug Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Rheumatoid Arthritis
4.1.2 Psoriatic Arthritis
4.1.3 Other
4.2 Global Xeljanz (tofacitnib) Drug Sales Value by Application
4.2.1 Global Xeljanz (tofacitnib) Drug Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Xeljanz (tofacitnib) Drug Sales Value, by Application (2019-2030)
4.2.3 Global Xeljanz (tofacitnib) Drug Sales Value, by Application (%) (2019-2030)
4.3 Global Xeljanz (tofacitnib) Drug Sales Volume by Application
4.3.1 Global Xeljanz (tofacitnib) Drug Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Xeljanz (tofacitnib) Drug Sales Volume, by Application (2019-2030)
4.3.3 Global Xeljanz (tofacitnib) Drug Sales Volume, by Application (%) (2019-2030)
4.4 Global Xeljanz (tofacitnib) Drug Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Xeljanz (tofacitnib) Drug Sales Value by Region
5.1.1 Global Xeljanz (tofacitnib) Drug Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Xeljanz (tofacitnib) Drug Sales Value by Region (2019-2024)
5.1.3 Global Xeljanz (tofacitnib) Drug Sales Value by Region (2025-2030)
5.1.4 Global Xeljanz (tofacitnib) Drug Sales Value by Region (%), (2019-2030)
5.2 Global Xeljanz (tofacitnib) Drug Sales Volume by Region
5.2.1 Global Xeljanz (tofacitnib) Drug Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Xeljanz (tofacitnib) Drug Sales Volume by Region (2019-2024)
5.2.3 Global Xeljanz (tofacitnib) Drug Sales Volume by Region (2025-2030)
5.2.4 Global Xeljanz (tofacitnib) Drug Sales Volume by Region (%), (2019-2030)
5.3 Global Xeljanz (tofacitnib) Drug Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Xeljanz (tofacitnib) Drug Sales Value, 2019-2030
5.4.2 North America Xeljanz (tofacitnib) Drug Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Xeljanz (tofacitnib) Drug Sales Value, 2019-2030
5.5.2 Europe Xeljanz (tofacitnib) Drug Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Xeljanz (tofacitnib) Drug Sales Value, 2019-2030
5.6.2 Asia Pacific Xeljanz (tofacitnib) Drug Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Xeljanz (tofacitnib) Drug Sales Value, 2019-2030
5.7.2 South America Xeljanz (tofacitnib) Drug Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Xeljanz (tofacitnib) Drug Sales Value, 2019-2030
5.8.2 Middle East & Africa Xeljanz (tofacitnib) Drug Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Xeljanz (tofacitnib) Drug Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Xeljanz (tofacitnib) Drug Sales Value
6.2.1 Key Countries/Regions Xeljanz (tofacitnib) Drug Sales Value, 2019-2030
6.2.2 Key Countries/Regions Xeljanz (tofacitnib) Drug Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Xeljanz (tofacitnib) Drug Sales Value, 2019-2030
6.3.2 United States Xeljanz (tofacitnib) Drug Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Xeljanz (tofacitnib) Drug Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Xeljanz (tofacitnib) Drug Sales Value, 2019-2030
6.4.2 Europe Xeljanz (tofacitnib) Drug Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Xeljanz (tofacitnib) Drug Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Xeljanz (tofacitnib) Drug Sales Value, 2019-2030
6.5.2 China Xeljanz (tofacitnib) Drug Sales Value by Type (%), 2023 VS 2030
6.5.3 China Xeljanz (tofacitnib) Drug Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Xeljanz (tofacitnib) Drug Sales Value, 2019-2030
6.6.2 Japan Xeljanz (tofacitnib) Drug Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Xeljanz (tofacitnib) Drug Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Xeljanz (tofacitnib) Drug Sales Value, 2019-2030
6.7.2 South Korea Xeljanz (tofacitnib) Drug Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Xeljanz (tofacitnib) Drug Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Xeljanz (tofacitnib) Drug Sales Value, 2019-2030
6.8.2 Southeast Asia Xeljanz (tofacitnib) Drug Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Xeljanz (tofacitnib) Drug Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Xeljanz (tofacitnib) Drug Sales Value, 2019-2030
6.9.2 India Xeljanz (tofacitnib) Drug Sales Value by Type (%), 2023 VS 2030
6.9.3 India Xeljanz (tofacitnib) Drug Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Pfizer
7.1.1 Pfizer Company Information
7.1.2 Pfizer Introduction and Business Overview
7.1.3 Pfizer Xeljanz (tofacitnib) Drug Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Pfizer Xeljanz (tofacitnib) Drug Product Offerings
7.1.5 Pfizer Recent Development
8 Industry Chain Analysis
8.1 Xeljanz (tofacitnib) Drug Industrial Chain
8.2 Xeljanz (tofacitnib) Drug Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Xeljanz (tofacitnib) Drug Sales Model
8.5.2 Sales Channel
8.5.3 Xeljanz (tofacitnib) Drug Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Pfizer

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂